Tesamorelin
A synthetic analog of growth-hormone-releasing hormone (GHRH) studied for endocrine signalling, lipid metabolism, and pulsatile growth-hormone axis research.
⏱ Half-Life
Short–Moderate duration profile
Tesamorelin demonstrates a short–moderate half-life characteristic in research literature, shaping how observation windows and study timelines are typically structured.
⚡ Onset Characteristics
Gradual measurable response
Onset is observed as gradual — a property that influences how researchers structure comparative studies versus other compounds in the signalling research category.
🧠 Key Notes
What makes it distinct
- 01Stabilised GHRH structure for extended research window
- 02Frequently compared with CJC-1295 in endocrine studies
- 03Investigated for visceral lipid metabolism pathways
🧬 Mechanism of Action
How it works
Tesamorelin is a stabilised 44-amino-acid analog of human growth-hormone-releasing hormone (GHRH), with a trans-3-hexenoic acid modification that protects against enzymatic degradation. It binds the GHRH receptor on pituitary somatotroph cells, stimulating endogenous growth hormone secretion in a natural pulsatile pattern. Unlike exogenous GH administration, it preserves physiological feedback loops and downstream IGF-1 signalling. Its effect on visceral adipose tissue is particularly well-characterised — IGF-1 and GH together promote lipolysis preferentially in visceral fat depots while sparing subcutaneous fat.
✨ Documented Benefits
What the research shows it supports
🔍 Research Insights
What the literature shows
FDA-approved for HIV-associated lipodystrophy — one of the few peptides in the library with full clinical-trial pharmacology data.
Preferentially reduces visceral adipose tissue while preserving subcutaneous fat in published studies.
Preserves natural pulsatile GH release, making it a more physiologic comparator than continuous GH administration.
🧪 Typical Research Use Cases
Where it appears in study design
Visceral adiposity and lipid metabolism research.
GH-axis modulation in endocrine models.
Comparative work vs CJC-1295 + Ipamorelin blends.
📚 References
Peer-reviewed literature
Primary research sources cited on this profile. All links resolve to PubMed or the publishing journal.
- [01]
Falutz, J. et al. (2007). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. Journal of Clinical Endocrinology & Metabolism, 95(9), 4291–4304.
J Clin Endocrinol Metab ↗ - [02]
Stanley, T. L. et al. (2014). Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA, 312(4), 380–389.
JAMA ↗ - [03]
Falutz, J. et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359–2370.
New England Journal of Medicine ↗ - [04]
Spooner, L. M., & Olin, J. L. (2012). Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Annals of Pharmacotherapy, 46(2), 240–247.
Annals of Pharmacotherapy ↗
Continue Exploring
Also explore: CJC-1295 + Ipamorelin, MOTS-c, Retatrutide